Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma

Primary effusion lymphoma (PEL) is a rare form of aggressive B cell lymphoma caused by Kaposi’s sarcoma-associated herpesvirus (KSHV). Current chemotherapy approaches result in dismal outcomes, and there is an urgent need for new PEL therapies. Previously, we established, in a direct xenograft model...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Bhatt, Shruti, Ashlock, Brittany M., Toomey, Ngoc L., Diaz, Luis A., Mesri, Enrique A., Lossos, Izidore S., Ramos, Juan Carlos
Format: Artigo
Jezik:Inglês
Izdano: American Society for Clinical Investigation 2013
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3668825/
https://ncbi.nlm.nih.gov/pubmed/23635777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI64503
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki